Rodman & Renshaw Terminates China Cord Blood Coverage

Loading...
Loading...
Rodman & Renshaw terminates its China Cord Blood
CO
coverage in a research report published today. Rodman & Renshaw's last rating for China Cord Blood was a Market Outperform / Speculative Risk rating and a $6 price target. In the report, Rodman & Renshaw states, "Effective immediately, we are terminating coverage of China Cord Blood Corp (CCBC) to better distribute resources throughout our coverage universe." Shares of China Cord Blood closed today at $3.55, up 1.45% from Thursday's market close.
Posted In: Analyst ColorAnalyst RatingsRodman & Renshaw
We simplify the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...